Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ginseng saponin IH901 in preparing angiogenesis inhibitor

A technology of angiogenesis inhibition and ginsenosides, which is applied to cardiovascular system diseases, anti-inflammatory agents, organic active ingredients, etc., can solve the problems of unseen ginsenoside IH901, increase myocardial contractility, etc.

Inactive Publication Date: 2009-07-08
厦门华侨亚热带植物引种园
View PDF7 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to literature and patent retrieval, it is reported that ginsenoside IH901 can be used as an anticancer drug or auxiliary drug (Chinese patent CN1623554), in increasing myocardial contractility (Chinese patent CN1879640), in the preparation of pharmaceuticals for the treatment or prevention of liver fibrosis The new application of ginsenoside IH901 (Chinese patent CN1679600), and the application in the prevention or treatment of arthritis (Chinese patent CN101147743), etc., have not seen the report of ginsenoside IH901 in inhibiting angiogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginseng saponin IH901 in preparing angiogenesis inhibitor
  • Application of ginseng saponin IH901 in preparing angiogenesis inhibitor
  • Application of ginseng saponin IH901 in preparing angiogenesis inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1 The effect of ginsenoside IH901 on the proliferation of ECV304 cells

[0030] 1) Experimental materials:

[0031] Cell line, culture medium: Human umbilical vein endothelial cells ECV304 were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences. Medium RPMI-1640 was purchased from GIBCO Company, fetal bovine serum was purchased from Hyclone Company, penicillin and streptomycin were purchased from Shanghai Sangong Company.

[0032] 2) Drugs: Ginsenoside IH901 is prepared according to the invention patent method whose publication number is CN1985865; other reagents 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (abbreviated as MTT), dimethyl sulfoxide (referred to as DMSO), etc. were purchased from Sigma or other domestic companies.

[0033] 3) Experimental method: A group of ginsenoside IH901 with a concentration of 0, 6.25, 12.5, 25, 50, 75, and 100 μM was applied to ECV304 respectively, and the different concentratio...

Embodiment 2

[0038] Example 2 Morphological observation of apoptosis induced by ginsenoside IH901 in ECV304 cells

[0039] 1) Experimental materials: Hoechst 33258, AO / EB were purchased from Calbiochem (San Diego, CA), paraformaldehyde was purchased from Shanghai Sangong Company, and other materials were as in Example 1.

[0040] 2) Experimental method:

[0041] (1) Inoculate the cells in the logarithmic growth phase on the coverslip, take out the slides after drug treatment for a predetermined time, and wash them with PBS for 3 times; (2) Fix with 4% paraformaldehyde for 10 min at room temperature, Wash with PBS for 3 times; (3) Hoechst 33258 staining: After incubating with 2 μl Hoechst 33258 (10 μg / ml) at room temperature for 5-10 minutes, observe under a fluorescent microscope; (4) AO / EB staining: treat treated adherent and After the suspended cells were collected together, they were resuspended with 2 μl of AO (100 μg / ml) and EB (100 μg / ml), observed and photographed under a fluoresce...

Embodiment 3

[0043] Example 3 Effect of ginsenoside IH901 on phase distribution of ECV304 cell cycle

[0044] 1) Experimental materials: Rnase A, Propidium iodide were purchased from Sigma, and other materials were as in Example 1.

[0045] 2) Experimental method:

[0046] (1) After the cells in the logarithmic growth phase were treated with ECV304 at 0, 25, 50, and 75 μM IH901 for 12 hours, all adherent and suspended cells were collected; (2) PBS was washed twice and then resuspended in PBS; (3) Fix with pre-cooled 70% ethanol at -20°C for 1 hour, and store at 4°C for testing; (4) remove ethanol after low-speed centrifugation, and wash twice with PBS; Incubate at ℃ for 30 minutes; (6) transfer to an ice bath, add PI (50 mg / ml) dye solution, and incubate at 4 ℃ in the dark for 20-30 minutes; (7) test on the machine.

[0047] 3) Experimental results: cell detection showed that: apoptotic cells increased with the increase of drug concentration, the apoptotic rates were 0.8±0.51%, 5.19±2.17...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Application of ginsenoside IH901 in preparing angiogenesis inhibitors relates to the application of the ginsenoside IH901 in the medicament field. The invention provides application of ginsenoside IH901 and a precursor thereof in preparing angiogenesis inhibitors. The ginsenoside IH901 is 20-O-beta-D-glucopyranoside-20(S)-protopanoxadiol which can be used for preparing the angiogenesis inhibitors, and the precursor of the ginsenoside IH901 can be used for preparing the angiogenesis inhibitors. The extracted ginsenoside IH901 and the precursor have inhibitory effect on infiltration metastasis and angiogenesis and are used for preparing medicaments for treating diseases related to tumor angiogenesis and other angiogenesis. The ginsenoside IH901 and precursor are prepared into anti-tumor drugs and other drugs for angiogenesis, thus providing a research base for pharmacodynamics and action mechanism and having values of developing the ginsenoside IH901 and the precursor into drugs for tumor chemotherapy and / or auxiliary chemotherapy.

Description

technical field [0001] The present invention relates to the application of ginsenoside IH901 in the field of medicine, in particular to the application of ginsenoside IH901 in the preparation of angiogenesis inhibitors. Background technique [0002] Angiogenesis is the growth of new capillary blood vessels originating from pre-existing capillaries and postcapillary venules. Blood vessels are an important way to transport oxygen, nutrients and metabolites, and it is difficult for tissues or organs to survive without vascular support, so angiogenesis occurs along with the formation of organs and tissues in the body. Tumor angiogenesis is a hot spot in tumor research in recent years. The method of inhibiting tumor angiogenesis can be used as an adjuvant anti-tumor therapy. Some experiments have also confirmed that inhibiting tumor angiogenesis can effectively inhibit tumor growth. Now, tumor angiogenesis has been used clinically as an indicator for evaluating the prognosis of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/575A61P43/00A61P35/00A61P9/10A61P29/00A61P19/02A61P17/06
Inventor 明艳林陈良华陈忠炎郑志忠童庆宣
Owner 厦门华侨亚热带植物引种园
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com